Antimicrobial Placebo-Control Trial Should Be Required By FDA – PhRMA
Executive Summary
Antimicrobial drug sponsors would be willing to conduct placebo-controlled trials in acute exacerbation of chronic bronchitis if FDA required such studies, Bristol-Myers Squibb VP-Infectious Disease & Clinical Development Roger Echols, MD, said
You may also be interested in...
Antibiotic Trials For COPD May Hinge On Patient-Reported Outcomes, FDA Says
Outcomes that are clinically important to patients should be the focus of clinical trials for antibiotics to treat acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease, FDA recommends in a 1draft guidance released Aug. 21
Antibiotic Trials For COPD May Hinge On Patient-Reported Outcomes, FDA Says
Outcomes that are clinically important to patients should be the focus of clinical trials for antibiotics to treat acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease, FDA recommends in a 1draft guidance released Aug. 21
FDA Collaborations With Industry Should Weigh Potential Conflicts Of Interest
FDA recommends that agency staff avoid partnering with industry or trade associations unless the benefit outweighs any potential conflicts of interest raised by such leveraging arrangements